Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Trial Profile

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs BLU-667 (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Proof of concept; Registrational; Therapeutic Use
  • Acronyms ARROW
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 04 Jan 2019 According to a Blueprint Medicines media release, Enrollment of previously treated NSCLC and MTC cohorts is expected to complete in the first half of 2019. Updated data will be presented in the first half of 2019.
    • 03 Jan 2019 Planned number of patients changed from 250 to 360.
    • 30 Oct 2018 According to a Blueprint Medicines media release, based on the additional data of this study, the company plans to submit an NDA for BLU-667 in the first half of 2020. The company recently received a written feedback from the US FDA supporting expedited development of BLU-667.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top